anti-HBe and anti-HBc were detected by enzyme linked immunosorbent assay (Kehua Bio-Engineering Co., Shanghai, China) or chemiluminescent assay (Elecsys 2010, Roche Diagnostics, Basel). HBV DNA was quantified by real-time PCR with a LightCycler detection system (ABI 7300 Realtime PCR system, USA) and with a commercial detection kit (Kehua Bio-Engineering). The lower limit of detection for this assay was 500 copies/ml.
Analysis of HBV genotyping and drug resistance
Serum HBV DNA was extracted from 200 μl serum, as described in the Qiagen DNA blood kit (Qiagen, Germany). The fragments (nt130-nt1129), encompassing the reverse transcriptase (RT) domain, were amplified by nested PCR. The first pair of primers for the PCR were 5'-AAGCTCTGCTAGATCCCAGAGT-3' (sense: nt18-nt40) and 5'-TTTCGCTCCAGACCGGCTGC-3' ( a n t i s e n s e : n t 1 3 2 0 -n t 1 
0 ) . T h e s e c o n d p a i r o f p r i m e r s f o r t h e P C R i n c l u d e d 5'-GCGGGGTTTTTCTTGTTGAC-3' (sense: nt56-nt75) and 5'-AGTATGGATCGGCAGAGGAG-3'
(antisense: nt1272-nt1253). The amplification reactions consisted of denaturation at 95℃ for 5 min, followed by 35 cycles of 95℃ for 30 s, 55℃ for 30 s, and 72℃ for 60 s, and a final extension at 72℃ for 5 min. PCR products were directly sequenced on an automated DNA sequencer (ABI 3730XL, USA) using the second sense primer. Substitutions at positions rt80, rt173, rt180, rt181, rt184, rt202, rt204, rt236, and rt250 were taken as resistance mutations for analysis. 18 HBV genotypes classification were based on phylogenetic analysis of the 1 225-bp-long S/Pol gene sequence as described previously.
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Construction of 1.24-fold genome HBV vectors
In order to investigate the effect of rtA181T/V mutations on HBV biological activity at cellular level between genotypes B and C, Ba_JPN58 and C_ JPNAT HBV plasmid kindly provided by Sugiyama, 20 were used as wild type templates to construct rtA181T and rtA181V mutations. Site directed mutagenesis (Stratagene, La Jolla, CA) were carried out to introduce mutations, respectively. The mutagenesis NAs therapy. A study from Hong Kong showed that there was no difference in the antiviral response and the rate of development of resistant mutations with genotypes B and C after treatment with lamivudine for one year. Another study from China reported that YMDD (tyrosine-methionine-aspartate-aspartate) mutant pattern was not different between patients with genotypes B and C. 16 On the contrary, Pan et al found that the YMDD mutation patterns and serum HBV DNA levels differ between lamivudine-resistant HBV genotypes B and C. 17 To date, there is a few data about the characteristics of rtA181 mutation in HBV genotypes B and C. In this study, we investigated the mutation patterns and clinical characteristics in rtA181 mutation patients, and detected virus particle and HBsAg in HepG2 cells encoding rtA181 mutation, with the aim to explore whether there were any differences in characteristics associated with the rtA181 mutation in HBV genotypes B and C.
MAtERiALS AND MEtHODS
Patients
Total of 85 patients with chronic HBV infection who visited Nanjing PLA 81st Hospital Liver Clinic Center from January 2010 to January 2012 were enrolled in the study. They were treated with NAs and scheduled follow up every 3-6 months. They exhibited viral breakthrough during antiviral treatment and were identified rtA181T or rtA181V mutations. Patients who received IFN-α treatment or co-infected with hepatitis C and hepatitis D virus, or human immunodeficiency virus were excluded from this study. The diagnostic criteria were based on the Management Scheme of Diagnostic and Therapy Criteria of Viral Hepatitis issued by the Chinese Society of Infectious Diseases.
Assay for liver function, serological marker and quantification of HBV DNA Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by the Olympus AU5400 Chemistry System (Beckman Coulter, Switzerland). HBsAg/anti-HBs, HBeAg/ primers were 181T-sense (5′-GCCCGTTTCTCCTGA CTCAGTTTACTAGTGCC-3′) and 181T-anti (5′-GGC ACTAGTAAACTGAGTCAGGAGAAACGGGC-3′), 181V-sense (5′-GCCCGTTTCTCCTGGTTCAGTTT ACTAGTGCC-3′) and 181V-anti (5′-GGCACTAGTA AACTGAACCAGGAGAAACGGGC-3′).
Cell culture and transfection experiments
HepG2 human hepatoma cells were cultured in Dulbecco's modified Eagle medium (DMEM, Gibco) as described before. 21 After 24 h of culture, cells were transiently transfected with 5 μg of HBV construct using FuGENE HD Transfection (Roche, Switzerland). Transfection efficiency was measured by cotransfection with 0.1 μg pSEAp and determination of alkaline phosphatase activity in cell supernatants using SEAP Reporter Assay Kit (Roche, Switzerland). Cell and supernatants were harvested for further analysis 3 day after transfection. All experiments were performed in triplicates. 
Relative replication and HBsAg expression yield assays
RESULtS
Clinical characteristics of patients
Total of 85 patients appeared rtA181T/V mutations after receiving NAs treatment for 10 months or more. Of them, 78 (91.8%) were males and 7 (7.2%) females, their mean age was 41 ± 10 years old. Concerning genotyping, genotype C was the largest group (70 patients, 84.3%), followed by genotype B (13 patients, 15.7%). Other genotypes were not detected in our study. After emergence of rtA181 mutant, the ALT and AST levels were statistically different from that at baseline (81.8 ± 49.1 U/L vs. 175.0 ± 130.2 U/L, P < 0.05; 70.6 ± 42.8 U/L vs. 125.0 ± 99.5 U/L, P < 0.05, respectively). HBV DNA levels were lower than that at baseline (4.10 ± 1.18 log 10 copies/ml vs. 5.97 ± 1.26 log 10 copies/ml, P < 0.05), and HBsAg titers were also different (3.50 ± 0.45 log 10 COI vs. 3.66 ± 0.36 log 10 COI, P < 0.05). However, from comparison of clinical characteristics of the patients between genotype B and C, no obvious difference was observed in mean age, sex ratio, ALT levels, AST levels, HBV DNA levels, HBsAg titers and HBeAg positive rate (P > 0.05). The data were shown in Table 1 .
Relationship between genotype and pattern of rtA181 mutation
Two patients were showed the presence of mixture mutant of rtA181T and rtA181V. Other patients represent the similar frequency of mutations with rtA181T (n = 44) compared with those with rtA181V (n = 39). The occurrence of all rtA181T mutation was lower in genotype B (30.8%) than in genotype C (55.6%), meanwhile the occurrence of all rtA181V was higher in genotype B (69.2%) than in genotype C (41.7%). However, these difference did not reach statistical significance (P > 0.05). Other mutations, combined with rtN236T or M204I/V mutation were also found no significant difference between genotypes B and C (P > 0.05). The data were shown in Table 2 . Notes: There was no significant difference between genotypes B and C (P > 0.05). For extracellular HBsAg, rtA181T clone was less than 1% of wild type, they were not available to be compared. different treatment effect with different genotypes.
In agreement with previous studies, our results showed that genotypes B and C were the major genotypes in China. 26, 28 In spite of emergence of rtA181 mutant, the patients' liver function, HBV DNA levels and HBsAg titers were lower than that at baseline, which suggested the antiviral drug still show effect to rtA181 mutant, or the mutant virus defective. These explained that after appearance of rtA181 mutant, many patients who continued previously treatment could still improve biochemical and virological results. This finding was similar to other studies in LAM resistance. 16 In vitro studies have found that the rtA181T mutation could affect the S gene aa172 from tryptophan to termination codon, resulting in loss of the C-terminal hydrophobic area in HBsAg, inhibiting the secretion of HBsAg from cell, leading to a decline in HBV DNA replication activity. 7 Our findings confirmed that little HBsAg or virons were secreted from cells transfected with rtA181T mutation not only in genotype B but also in genotype C. HBV encoding rtA181V has a moderate secretion defect, suggested that rtA181V mutation affect the surface protein exchange and have little influence on virus secretion. 27 Through this study, no differences of clinical characteristics and cellular results were found in rtA181 mutation of HBV genotypes B and C. Determination of HBV genotypes was probably not an important factor to predict antiviral responses in genotypes B and C.
DiSCUSSiON
The various HBV genotypes have different geographical distributions worldwide. 22 In China, genotypes B and C are the two most commonly found genotypes, that contributing 90% of the population of chronic hepatitis B patients. The clinical importance of genotype related differences in CHB patients remains incompletely understood. In LAM associated rtM204 mutation patients, some studies have confirmed that there was no difference in the antiviral response and the rate of development mutations in patients between different genotypes. 16, [23] [24] [25] In rtA181 resistant patients, Li et al showed that rtA181V mutation was more often seen in HBV genotype C2, 26 while others argued that rtA181T/V occurrence was not associated with genotypes. 27, 28 Based on these, we sought to examine whether there were any differences in genotypes B and C by assessing clinical and cellular characteristics. Unfortunately, we could not demonstrate any difference between genotypes B and C in terms of rtA181 mutant patterns, biochemical severity, HBsAg titers, HBV DNA levels, HBeAg status and mutations patterns in this study. Additionally, in vitro cell transfection study confirmed our clinical results. There were no differences in the replication and HBsAg expression of plasmids carrying rtA181T/V mutation between genotypes B and C. In patients treated with interferon, HBV genotype probably is an important factor to predict antiviral response. Genotype B has a more favourable response compared to genotype C, and genotype A is prior to genotype D. This favourable response may not apply in oral NAs therapy. The underlying mechanism may lies in the different action modes of the two antiviral drugs. NAs act through suppression the virus replication, while interferon acts through boosting the immune response against the virus. HBV genotypes lead to different virulence and pathogenicity, 29 which may induce different immune response in the host. Therefore, patients may have a better effect to interferon that stimulated a more pronounced immune response. As the response to NAs may not act via the immune system, the patients would not have the
